This episode focused on the most pressing unmet needs in RSV prevention and the clinical impact of newly approved options. Tan highlighted a key issue from the initial rollout of nirsevimab: supply ...

As RSV prevention tools expanded, clinicians faced new decisions around allocation, coordination, and outreach. In the final installment of this 3-part HCP Live Network RX Review roundtable, moderator ...

The new-look Advisory Committee on Immunization Practices (ACIP) will meet on June 25 and 26, 2025, for the first time since Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. replaced ...

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants and young children, placing a significant burden on families, hospitals, and the healthcare system. Recent ...

Global developmental delay (GDD) and intellectual disability (ID) affect an estimated 1% to 3% of children worldwide and are among the most common neurodevelopmental conditions encountered in ...

Primary care providers may be the first line of defense for children with pediatric acute-onset neuropsychiatric syndrome (PANS), but diagnosing and managing the condition can present significant ...

The FDA has accepted a new drug application (NDA) for epinephrine sublingual film (Anaphylm; Aquestive Therapeutics) to treat type 1 allergic reactions, including anaphylaxis. With the acceptance of ...

Michael O. Daines, MD, division chief of Pediatric Allergy and Immunology at the University of Arizona College of Medicine and principal investigator of the phase 3 trial evaluating Panzyga for ...

The FDA will not meet a prescription drug user fee act (PDUFA) date of June 17, 2025, for a decision regarding the potential approval of sebetralstat (KalVista Pharmaceuticals) to treat hereditary ...

A nationwide study from Karolinska Institutet has found a significant association between adverse childhood experiences (ACEs) and the risk of being diagnosed with endometriosis later in life. Drawing ...

Adolescents who are frequently exposed to cannabis or e-cigarette-related content on social media—particularly from friends and influencers—may be more likely to initiate substance use, according to ...

On June 18, Biogen announced the dosing of participants in the BRAVE study (NCT06953583), a global phase 3 clinical trial evaluating omaveloxolone (Skyclarys) in children aged 2 to younger than 16 ...